Volumetric regression ratio of the primary tumor and metastatic lymph nodes after induction chemotherapy predicts overall survival in head and neck squamous cell carcinoma
Olgun Eliçin(University of Bern), Daniel M. Aebersold(University of Bern), Pirus Ghadjar(Humboldt-Universität zu Berlin), A Geretschlaeger, Daniel Rauch(Washington University in St. Louis), Roland Giger(University of Bern), M Schmuecking, Ludwig Plaßwilm(University of St. Gallen), Pınar Ambarcıoğlu
Refubium (Universitätsbibliothek der Freien Universität Berlin)
January 1, 2016
Cited by 0
Related Papers
Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial
|The Lancet|2015|392
Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial
|The Lancet Respiratory Medicine|2017|184
Sorafenib with or without everolimus in patients with advanced hepatocellular carcinoma (HCC): a randomized multicenter, multinational phase II trial (SAKK 77/08 and SASL 29)
|Annals of Oncology|2016|140